Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 StudyPatrick Neven, Nicole Stahl, Maria Vidal, et al.
Biomedicines|July 2, 2021
The NHance<sup>®</sup> Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer PatientsPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
NPJ Breast Cancer|January 6, 2024
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)Magdalena Mileva, Elisabeth G E de Vries, Thomas Guiot, et al.
Breast Cancer Research and Treatment|July 10, 2026
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN studyDiogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, et al.
The New England Journal of Medicine|April 21, 2021
Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerAditya Bardia, Sara A Hurvitz, Sara M Tolaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD TrialFrancois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, et al.
Oncotarget|May 15, 2018
The clinical impact of using complex molecular profiling strategies in routine oncology practiceJean-François Laes, Philippe Aftimos, Philippe Barthelemy, et al.
NPJ Precision Oncology|March 11, 2025
A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancerPieter-Jan Volders, Philippe Aftimos, Franceska Dedeurwaerdere, et al.
The New England Journal of Medicine|December 11, 2024
Imlunestrant with or without Abemaciclib in Advanced Breast CancerKomal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Pageof 9